Tofacitinib for Inflammatory Eye Disease

• Status: Active, not recruiting
• Trial end date: 2021-04-04
• Target enrollment: 0
• Participant gender: All

Summary

Non-infectious inflammatory eye disease, such as uveitis and scleritis, is a chronic, auto-immune process that leads to vision loss. While steroids are effective in the short term, the side-effect profile of chronic steroid use necessitates the identification of effective steroid-sparing therapies. Tofacitinib is a small molecule that inhibits the signaling pathways of multiple inflammatory cytokines. The investigators plan to evaluate whether tofacitinib may have efficacy for patients with uveitis and / or scleritis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• diagnosis of uveitis

• a clinical response to steroids

• active disease requiring at least 10mg of prednisone daily (or steroid equivalent)

Exclusion Criteria:

• suspected or confirmed ocular infection

• chronic or recurring infections, such as HIV

• renal insufficiency that would preclude safe administration of tofacitinib